- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Hillsdale Today
By the People, for the People
Quantbot Technologies LP Increases NovoCure Limited Stake
Institutional investor boosts holding in medical device company by over 160%
Published on Mar. 4, 2026
Got story updates? Submit your updates here. ›
Quantbot Technologies LP, an investment management firm, has significantly increased its stake in NovoCure Limited (NASDAQ:NVCR), a medical equipment provider. According to a regulatory filing, Quantbot lifted its holdings in NovoCure shares by 163.6% during the third quarter of the previous year.
Why it matters
NovoCure is a global oncology company pioneering a novel cancer treatment technology called Tumor Treating Fields (TTFields). The substantial increase in Quantbot's stake suggests the investment firm sees strong potential in NovoCure's innovative approach and future growth prospects.
The details
In its most recent disclosure with the Securities and Exchange Commission, Quantbot Technologies LP reported that it now owns 195,515 shares of NovoCure, up from 74,161 shares held in the prior quarter. This represents an increase of 163.6% in Quantbot's position. The firm's total investment in NovoCure is now valued at approximately $2.53 million.
- Quantbot Technologies LP increased its NovoCure stake in the 3rd quarter of the previous year.
The players
Quantbot Technologies LP
An investment management firm that has significantly increased its stake in NovoCure Limited.
NovoCure Limited
A global oncology company pioneering a novel cancer treatment technology called Tumor Treating Fields (TTFields).
The takeaway
Quantbot Technologies' substantial increase in its NovoCure holdings suggests the investment firm sees strong potential in the medical device company's innovative cancer treatment approach and future growth prospects. This move highlights the growing investor interest in novel cancer therapies like NovoCure's Tumor Treating Fields technology.
